Fact CheckerSign in

NCT07647471Recruiting

Evaluation of an Exercise Intervention During Intensive Medical Treatment in Pediatric Oncology.

Evaluation of an Exercise Intervention During Intensive Medical Treatment in Pediatric Oncology (Evaluation BEwegungs- Und sPorttherapeutischer Interventionen Unter Medizinischer Therapie in Der Pädiatrischen Onkologie)

Source: ClinicalTrials.gov · Last updated 11 Sept 2026

Brief summary (registry, in English)

The BEPPO study is a Germany-wide clinical trial investigating whether a structured exercise program can improve physical and mental health in children and adolescents undergoing cancer treatment. Although exercise is known to support recovery and well-being, it is not yet a standard part of pediatric oncology care. The study aims to generate evidence to support the integration of exercise into routine treatment. A total of 346 patients aged 3 to 18 years are recruited across 13 pediatric oncology centers in Germany. Participants are randomly assigned to either an exercise intervention group or a standard care control group. Children in the intervention group take part in a 6-month individualized exercise program with 3-5 sessions per week. The program is delivered across different settings, including inpatient hospital care, outpatient treatment, and home-based training supported by telemedicine. This ensures continuous support throughout the course of medical treatment. In addition to supervised exercise sessions, participants receive four structured counseling sessions. These sessions aim to strengthen motivation, address individual barriers to participation, and support long-term engagement in physical activity. The counseling also helps build a strong therapeutic relationship and promotes adherence to the program. The exercise intervention is based on established principles of sports science but is individually adapted to each patient's health status, treatment phase, and personal preferences. Each training session follows a structured plan with specific goals, while also considering individual physical and psychological conditions to ensure safety, feasibility, and effectiveness. The main objective of the BEPPO study is to improve physical performance, particularly leg strength, which is the primary endpoint. Secondary outcomes include endurance, functional mobility, balance, physical activity levels, fatigue, quality of life, mental well-being, frailty, and treatment-related symptoms and side effects. In addition to clinical effectiveness, the study also evaluates how well the intervention can be implemented in routine healthcare settings. This includes assessing adherence, feasibility, and potential barriers and facilitators for integrating exercise into standard care. A health economic evaluation is also conducted in collaboration with health insurance providers to determine cost implications. Overall, the BEPPO study aims to provide robust scientific evidence on the benefits and feasibility of structured exercise during pediatric cancer treatment. The long-term goal is to establish exercise as a standard component of supportive care in pediatric oncology, improving both short- and long-term outcomes for patients.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
346 (estimated)
First submitted
9 Jun 2026
Start date
1 Jul 2026
Primary completion date
31 Dec 2028
Lead sponsor
Universität Duisburg-Essen
NCT number
NCT07647471

What you commit to

  • Study type: Interventional
  • Planned participants: 346
  • From 1 Jul 2026 to the primary completion date, 31 Dec 2028
  • 13 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • No active medical oncological treatment (e.g., watch-and-wait strategy, surgery without ongoing oncological acute treatment at a pediatric oncology center)

Age

  • Patients aged \<3 and \>18 years

Other

  • Medical limitations that do not allow implementation of the study protocol
  • Life expectancy \< 6 months
  • Patients not insured by German statutory health insurers (e.g., Privatly insured patients, self-paying patients)

Who the study is looking for

  • Patients aged ≥3 and ≤18 years
  • Oncological diagnosis with curative treatment intent
  • ≤6 weeks since cancer diagnosis (diagnosis can be initial, secondary or relapse diagnosis)
  • Information and consent procedures feasible in German, English or with using local site resources (e.g., interpreters or multilingual staff)
  • Communication with the patient is possible in German, English or with using local site resources (e.g., interpreters or multilingual staff) during the assessments and intervention
  • Patients insured by German statutory health insurers

Age in the registry: 3 years to 18 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (13)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Charité-Universitätsmedizin Berlin, Department of Pediatric Oncology/Hematology
Coordinator of this site? Confirm its status
BerlinGermanyRecruiting
University of Bonn Medical Center, Department of Pediatric Hematology/Oncology,
Coordinator of this site? Confirm its status
BonnGermanyRecruiting
Children's Hospital Amsterdamer Straße, ; Clinic for Children and Youth Medicine; Department for pediatric hematology/oncology
Coordinator of this site? Confirm its status
CologneGermanyRecruiting
University Hospital Cologne, Department of Pediatric Oncology and Hematology, Children's Hospital
Coordinator of this site? Confirm its status
CologneGermanyRecruiting
University Hospital Essen, Department of Pediatric Hematology/Oncology, Center for Child and Adolescent Medicine, Clinic for Pediatrics III
Coordinator of this site? Confirm its status
EssenGermanyRecruiting
Universitätsmedizin Frankfurt, Department of Pediatrics, Pediatric Oncology and Haematology
Coordinator of this site? Confirm its status
FrankfurtGermanyRecruiting
Universitätsklinikum Hamburg-Eppendorf, Department of Pediatric Hematology and Oncology, Hubertus Wald Tumor Center, University Cancer Center Hamburg
Coordinator of this site? Confirm its status
HamburgGermanyRecruiting
Universitätsklinikum Jena, Klinik für Kinder- und Jugendmedizin
Coordinator of this site? Confirm its status
JenaGermanyRecruiting
Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Department of Pediatric Hematology/Oncology
Coordinator of this site? Confirm its status
MainzGermanyRecruiting
Pädiatrische Hämatologie und Onkologie, Zelltherapie Zentrum für Kinder- und Jugendmedizin Eine Kooperation der München Klinik und des TUM Klinikums
Coordinator of this site? Confirm its status
MünchenGermanyRecruiting
DIAKONEO Klinik Hallerwiese-Cnopfsche Kinderklinik Nürnberg, Department of Pediatric Hematology and Oncology
Coordinator of this site? Confirm its status
NurembergGermanyRecruiting
Klinikum der Landeshauptstadt Stuttgart, Zentrum für Kinder-, Jugend- und Frauenmedizin, Pädiatrie
Coordinator of this site? Confirm its status
StuttgartGermanyRecruiting
University Medical Center Ulm, Department of Pediatrics and Adolescent Medicine
Coordinator of this site? Confirm its status
UlmGermanyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.